Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN
Files
Publication date
2019-01-01
Authors
de Ridder, Lissy
Assa, Amit
Bronsky, Jiri
Romano, Claudio
Russell, Richard K.
Afzal, Nadeem A.
Hauer, Almuthe C.
Knafelz, Daniela
Lionetti, Paolo
Strisciuglio, Caterina
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
TBiologic therapies have changed the outcome of both adult and pediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, the first biosimilar of infliximab was introduced into the pharmaceutical market. In 2015, a first position paper on the use of biosimilars in pediatric IBD was published by the ESPGHAN IBD Porto group. Since then, more data have accumulated for both adults and children demonstrating biosimilars are an effective and safe alternative to the originator. In this updated position statement, we summarize current evidence and provide joint consensus statements regarding the recommended practice of biosimilar use in children with IBD.
Keywords
Crohn disease, biologics, biosimilars, inflammatory bowel disease, pediatric, ulcerative colitis, Taverne, Pediatrics, Perinatology, and Child Health, Gastroenterology
Citation
de Ridder, L, Assa, A, Bronsky, J, Romano, C, Russell, R K, Afzal, N A, Hauer, A C, Knafelz, D, Lionetti, P, Strisciuglio, C, Veres, G, Winter, H, Wolters, V M, Sladek, M, Vulto, A G, Dias, J A & Paediatric IBD Porto group of ESPGHAN 2019, 'Use of Biosimilars in Pediatric Inflammatory Bowel Disease : An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN', Journal of Pediatric Gastroenterology and Nutrition, vol. 68, no. 1, pp. 144-153. https://doi.org/10.1097/MPG.0000000000002141